# US 2012/0251544 A1 · Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251544 A1
- Document ID: US20120251544A1
- Status: Published application
- Kind: A1
- Application number: 13/494,912
- Filed: 2012-06-12
- Published: 2012-10-04
- Earliest claimed: 2007-08-23
- Assignees: Amgen Inc.
- Inventors: Simon Mark Jackson; Nigel Pelham Clinton Walker; Derek Evan Piper; Bei Shan; Wenyan Shen; Joyce Chi Yee Chan; Chadwick Terence King; Randal Robert Ketchem; Christopher Mehlin; Teresa Arazas Carabeo; Qiong Cao
- Web page: https://patentgrep.com/patent/US20120251544A1

## CPC

- C07K 16/40: against enzymes
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/66: Phosphorus compounds
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 2039/505: {comprising antibodies}
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

An isolated neutralizing antigen binding protein that binds to a PCSK9 protein comprising the amino acid sequence of SEQ ID NO: 1, wherein the neutralizing antigen binding protein decreases the LDLR lowering effect of PCSK9 on LDLR, wherein the antigen binding protein is a LDLR non-competitive neutralizing antigen binding protein.

### Claim 38 (depends on 37)

The isolated neutralizing antigen binding protein of claim 37, wherein the antigen binding protein binds to PCSK9 with a Kd that is less than 100 pM.

### Claim 39 (depends on 37)

The isolated PCSK9 neutralizing antigen binding protein of claim 37, wherein the antigen binding protein binds specifically to the V domain of PCSK9 (amino acids 540-691 of SEQ ID NO: 3).

### Claim 40 (depends on 37)

The isolated PCSK9 neutralizing antigen binding protein of claim 37, wherein the antigen binding protein binds within amino acids 600-692 of SEQ ID NO: 3.

### Claim 41 (depends on 37)

The antigen binding protein of claim 37, wherein the antigen binding protein binds to human PCSK9 with an equilibrium dissociation constant (KD) of about 1000 pM or less.

### Claim 42 (depends on 37)

The antigen binding protein of claim 37, wherein the antigen binding protein binds to human PCSK9 with an equilibrium dissociation constant (KD) of about 100 pM or less.

### Claim 43

An isolated antigen binding protein that binds to PCSK9, wherein the antigen binding protein comprises:
a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 74; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 74; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 74 and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 5; a light chain CDR2 that a CDR2 in SEQ ID NO: 5; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 5;
a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 69; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 69; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 69 and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 42; a light chain CDR2 that a CDR2 in SEQ ID NO: 42; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 42;
a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 91; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 91; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 91 and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 28; a light chain CDR2 that a CDR2 in SEQ ID NO: 28; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 28;
a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 89; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 89; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 89 and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 32; a light chain CDR2 that a CDR2 in SEQ ID NO: 32; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 32;
a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 81; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 81; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 81 and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 44; a light chain CDR2 that a CDR2 in SEQ ID NO: 44; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 44;
a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 85; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 85; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 85 and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 7; a light chain CDR2 that a CDR2 in SEQ ID NO: 7; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 7; or
a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 87; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 87; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 87 and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 13; a light chain CDR2 that a CDR2 in SEQ ID NO: 13; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 13.

### Claim 44 (depends on 43)

The isolated antigen binding protein of claim 43,
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 89; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 89; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 89 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 32; the light chain CDR2 that the CDR2 in SEQ ID NO: 32; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 32;
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 81; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 81; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 81 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 44; the light chain CDR2 that the CDR2 in SEQ ID NO: 44; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 44;
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 85; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 85; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 85 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 7; the light chain CDR2 that the CDR2 in SEQ ID NO: 7; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 7; or
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 87; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 87; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 87 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 13; the light chain CDR2 that the CDR2 in SEQ ID NO: 13; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 13.

### Claim 45 (depends on 43)

The isolated antigen binding protein of claim 43, wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 89; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 89; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 89 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 32; the light chain CDR2 that the CDR2 in SEQ ID NO: 32; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 32.

### Claim 46 (depends on 43)

The isolated antigen binding protein of claim 43, wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 81; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 81; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 81 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 44; the light chain CDR2 that the CDR2 in SEQ ID NO: 44; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 44.

### Claim 47 (depends on 43)

The isolated antigen binding protein of claim 43, wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 85; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 85; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 85 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 7; the light chain CDR2 that the CDR2 in SEQ ID NO: 7; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 7.

### Claim 48 (depends on 43)

The isolated antigen binding protein of claim 43, wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 87; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 87; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 87 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 13; the light chain CDR2 that the CDR2 in SEQ ID NO: 13; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 13.

### Claim 49 (depends on 43)

The isolated antigen binding protein of claim 43,
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 74; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 74; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 74 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 5; the light chain CDR2 that the CDR2 in SEQ ID NO: 5; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 5;
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 69; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 69; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 69 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 42; the light chain CDR2 that the CDR2 in SEQ ID NO: 42; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 42;
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 91; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 91; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 91 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 28; the light chain CDR2 that the CDR2 in SEQ ID NO: 28; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 28;
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 89; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 89; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 89 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 32; the light chain CDR2 that the CDR2 in SEQ ID NO: 32; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 32; or
wherein the heavy chain polypeptide comprises the following complementarity determining regions (CDRs): the heavy chain CDR1 that is the CDR1 in SEQ ID NO: 81; the heavy chain CDR2 that is the CDR2 in SEQ ID NO: 81; the heavy chain CDR3 that is the CDR3 in SEQ ID NO: 81 and the light chain polypeptide comprises the following CDRs: the light chain CDR1 that is the CDR1 in SEQ ID NO: 44; the light chain CDR2 that the CDR2 in SEQ ID NO: 44; and the light chain CDR3 that is the CDR3 in SEQ ID NO: 44.

### Claim 50 (depends on 43)

The isolated antigen binding protein of claim 43, wherein the antigen binding protein is a neutralizing antigen binding protein.

### Claim 51 (depends on 43)

The isolated antigen binding protein of claim 43, wherein the antigen binding protein is a non-competitive antigen binding protein.

### Claim 52 (depends on 51)

The isolated antigen binding protein of claim 51, wherein the antigen binding protein is a neutralizing antigen binding protein.

### Claim 53

An isolated PCSK9 neutralizing antigen binding protein that binds within amino acids 600-692 of SEQ ID NO: 3.

### Claim 54 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

An isolated neutralizing antigen binding protein that competes for binding to PCSK9 with the antigen binding protein of any one or more of claims 37-53.

### Claim 55 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A pharmaceutical composition comprising at least one antigen binding protein of one or more of claims 37-54; and a pharmaceutically acceptable excipient.

### Claim 56 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A method of lowering serum cholesterol level in a subject, said method comprising administering to a subject an effective amount of an isolated neutralizing antigen binding protein of any one of claims 37-54.

### Claim 57 (depends on 56)

The method of claim 56, further comprising administering a therapeutically effective amount of a statin to the subject.

### Claim 58 (depends on 57)

The method of claim 57, wherein the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and any combination thereof.
